BioVest International is invested in biotechnology. BioVest operates the National Cell Culture Center and offers cell culture systems and related services to research institutions, biotech firms, and pharmaceutical companies. The company has an agreement with the National Cancer Institute to develop a therapeutic cancer vaccine for follicular lymphoma. BioVest also manufactures hollow fiber perfusion instruments for use in labs. BioVest is owned by Accentia, whose ultimate parent is Johns Hopkins.